Update on new therapeutic options for the somatopause

Acta Biomedica

Volumn 81, Issue SUPPL. 1, 2010, Pages 67-72

  Ceda, Gian Paolo ^a,b   Dall'Aglio, Elisabetta ^a,b   Morganti, Simonetta ^a,b   Denti, Licia ^a,b   Maggio, Marcello ^a,b   Lauretani, Fulvio ^b   Artoni, Andrea ^a,b   Ceresini, Graziano ^a,b   Cattabiani, Chiara ^a,b   Valenti, Giorgio ^a,b  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Aging; GH replacement therapy; GH secretagogues; IGF 1

Indexed keywords

GHRELIN; HUMAN GROWTH HORMONE; IBUTAMOREN; INDOLE DERIVATIVE; SOMATOMEDIN C; SPIRO COMPOUND;

AGED; AGING; CHRONIC DISEASE; FRAIL ELDERLY; HEART FAILURE; HORMONE SUBSTITUTION; HUMAN; KIDNEY DISEASE; METABOLISM; OBESITY; PHYSIOLOGY; REVIEW;

AGED; AGING; CHRONIC DISEASE; FRAIL ELDERLY; GHRELIN; HEART FAILURE; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; INDOLES; INSULIN-LIKE GROWTH FACTOR I; KIDNEY DISEASES; OBESITY; SPIRO COMPOUNDS;

EID: 77954902968     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56: M146-156.
2. Bandeen-Roche K, Xue OL, Ferrucci L, et al. Phenotype of frailty: characterization in the women's health and aging studies. J Gerontol A Biol Sci Med Sci 2001; 61: A262-266.
3. Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci 2007; 62: 722-7.
4. Lang T, Streeper T, Cawthon P, Baldwin K, Taaffe DR, Harris TB. Sarcopenia: etiology, clinical consequences, intervention, and assessment. Osteoporos Int 2009 Sep 25. DOI 10.1007/s00198-009-1059-y [Epub ahead of print].
5. Fryburg DA, Gelfand RA, Barrett EJ. Growth hormone acutely stimulates forearm muscle protein synthesis in normal humans. Am J Physiol 1991; 260: E499-504.
6. Feldt-Rasmussen U, Wilton P, Jonsson P. Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults. Growth Horm IGF Res 2004;14 Suppl A: S51-8.
7. Monson JP. Long-term experience with GH replacement therapy: efficacy and safety. Eur J Endocrinol 2003; 148 Suppl 2: S9-14.
8. Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990; 323: 1-6.
9. Liu H, Bravata DM, Olkin I, et al. Systematic Review: The Safety and Efficacy of Growth Hormone in the Healthy Elderly. Ann Intern Med 2007; 146: 104-15.
10. Blackman MR, Sorkin JD, Münzer T, et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 2002; 288: 2282-92.
11. Colao AM. The GH-IGF-I axis and the cardiovascular system: clinical implications. Clin Endocrinol 2008; 69: 347-58.
12. Juul A, Scheike T, Davidsen MJ, Gyllenborg T, Jorgensen JO. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a populationbased case-control study. Circulation 2002; 106: 939-44.
13. Vasan RS, Sullivan LM, D'Agostino RB, et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann Int Med 2003; 139: 642-8.
14. Denti L, Annoni V, Cattadori E, et al. Insulin-like growth factor 1 as a predictor of ischemic stroke outcome in the elderly. Am J Med 2004; 117: 312-7.
15. Le Corvoisier P, Hittinger L, Chanson P, Montagne O, Macquin-Mavier I, Maison P. Cardiac Effects of Growth Hormone Treatment in Chronic Heart Failure: A Meta-Analysis. J Clin Endocrinol Metab 2007; 92: 180-5.
16. Nagaya N, Moriya J, Yasumura Y, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 2004; 110: 3674-9.
17. Cittadini A, Saldamarco L, Marra AM, et al. Growth hormone deficiency in patients with chronic heart failure and beneficial effects of its correction. J Clin Endocrinol Metab 2009; 94: 3329-36.
18. Feldt-Rasmussen B, Lange M, Sulowicz W, et al. Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. J Am Soc Nephrol 2007; 18: 2161-71.
19. Kopple JD, Cheung AK, Christiansen JS, et al. Opportunity: a randomized clinical trial of growth hormone on outcome in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1741-51.
20. Mekala KC, Tritos NA. Effects of recombinant human growth hormone therapy in obesity in adults: a metaanalysis. J Clin Endocrinol Metab 2009; 94: 130-7.
21. Attallah H, Friedlander AL, Nino-Murcia M, Hoffman AR. Effects of growth hormone and pioglitazone in viscerally obese adults with impaired glucose tolerance: a factorial clinical trial. PLOS Clin Trial 2007; 2(5): e21. doi: 10.1371/journal.pctr.0020021
22. Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the growth hormone (GH)-insulin like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab 1996; 81: 4249-57.
23. Bach MA, Gormley GJ. Clinical use of growth hormone secretagogues. In Human Growth Hormone Research and Clinical Practice. R.G. Smith & M.O. Thorner, Eds. Humana Press. New Jersey, 2000: 315-34.
24. Bach MA, Rockwood K, Zetterberg C, et al. The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. J Am Geriatr Soc 2004; 52: 516-23.
25. Murphy MG, Weiss S, Mcclung M, et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2001; 86: 1116-25.
26. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 2008; 149: 601-11.
27. White HK, Petrie CD, Landschulz W, et al. Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab 2009; 94: 1198-206.
28. Torres-Aleman. Minireview: Mouse Models of Alzheimer's Dementia: Current Concepts and New Trends. Endocrinology 2008; 149: 5952-7.
29. Sevigny JJ, Ryan JM, van Dyck CH, Peng Y, Lines CR, Nessly ML, MS On behalf of the MK-677 Protocol 30 Study Group. Growth hormone secretagogue MK-677: No clinical effect on AD progression in a randomized trial. Neurology 2008; 71: 1702-8.
30. Kim MJ, Morley JE. The hormonal fountains of youth: myth or reality? J Endocrinol Invest 2005; 28 (11 Suppl Proceedings): 5-14.